Leiomyoma of the uterus at present: from pathogenesis to prospects for drug therapy
Clinical review for general practice · 19.06.2026 · 7 (4) · 93-98
DOI: 10.47407/kr2026.7.4.00827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Mekan R Orazov und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The reality of routine gynecological practice demonstrates a significant increase in the prevalence of proliferative disease entities in the overall structure of morbidity. Leiomyoma of the uterus is still among the best known and most prevalent benign hyperproliferative disorders. The review highlights new aspects of pathogenesis, considers advanced options for medication management of leiomyoma of the uterus, one of which are gonadotropin-releasing hormone antagonists. Relugolix 40 mg in combination with the add-back therapy represents one of the most promising, effective, and safe options for the pathogenetically substantiated treatment of leiomyoma of the uterus in the long term. Keywords: uterine fibroid, leiomyoma, pathogenesis, gestogens, gonadotropin-releasing hormone antagonists, Relugolix, norethisterone acetate, estradiol hemihydrate.
Zitieren
APA
Orazov, M. R., & Dolgov, E. D. (2026). Leiomyoma of the uterus at present: from pathogenesis to prospects for drug therapy. Clinical review for general practice, 7(4), 93-98. https://doi.org/10.47407/kr2026.7.4.00827
Vancouver
Orazov MR, Dolgov ED. Leiomyoma of the uterus at present: from pathogenesis to prospects for drug therapy. Clinical review for general practice. 2026;7(4):93-98. doi:10.47407/kr2026.7.4.00827
BibTeX
@article{Orazov2026,
author = {Orazov, Mekan R and Dolgov, Evgeny D},
title = {Leiomyoma of the uterus at present: from pathogenesis to prospects for drug therapy},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {93--98},
doi = {10.47407/kr2026.7.4.00827}
}
EUVIMED